Managed Asset Portfolios LLC Buys 3,866 Shares of Johnson & Johnson (NYSE:JNJ)

Managed Asset Portfolios LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 2.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 167,332 shares of the company’s stock after buying an additional 3,866 shares during the quarter. Johnson & Johnson makes up 3.8% of Managed Asset Portfolios LLC’s holdings, making the stock its 8th largest position. Managed Asset Portfolios LLC’s holdings in Johnson & Johnson were worth $27,118,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Sompo Asset Management Co. Ltd. boosted its holdings in Johnson & Johnson by 6.5% during the third quarter. Sompo Asset Management Co. Ltd. now owns 65,516 shares of the company’s stock worth $10,618,000 after buying an additional 4,010 shares in the last quarter. Wescott Financial Advisory Group LLC raised its position in shares of Johnson & Johnson by 22.4% in the third quarter. Wescott Financial Advisory Group LLC now owns 20,358 shares of the company’s stock worth $3,299,000 after acquiring an additional 3,721 shares during the period. Lane & Associates LLC boosted its stake in shares of Johnson & Johnson by 8.8% during the 3rd quarter. Lane & Associates LLC now owns 4,627 shares of the company’s stock worth $750,000 after acquiring an additional 376 shares in the last quarter. Truepoint Inc. increased its stake in shares of Johnson & Johnson by 26.9% in the 3rd quarter. Truepoint Inc. now owns 4,899 shares of the company’s stock valued at $794,000 after purchasing an additional 1,038 shares in the last quarter. Finally, KKM Financial LLC raised its holdings in Johnson & Johnson by 5.2% in the 3rd quarter. KKM Financial LLC now owns 17,376 shares of the company’s stock worth $2,816,000 after purchasing an additional 860 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent analyst reports. Morgan Stanley boosted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Citigroup raised their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Trading Down 0.2 %

Shares of Johnson & Johnson stock opened at $155.17 on Friday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $373.59 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 2.76 and a beta of 0.53. The stock has a 50 day moving average of $160.21 and a 200 day moving average of $156.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the company earned $2.66 EPS. The company’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.20%. Johnson & Johnson’s payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.